TFX TELEFLEX INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 96943 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.9%
TTM net income YoY192.9%
TTM EPS YoY212.3%
Revenue 3-yr CAGR-8.6%
Net income 3-yr CAGR-9.0%
Margins
Gross margin58.3%
Operating margin9.4%
Net margin13.5%
FCF margin3.9%
EBITDA margin18.7%
Returns
ROE8.3%
ROA4.3%
ROIC (approx.)3.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.46x
Current ratio2.01x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio2.3%
Payout ratio19.3%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-28 | 2025Q22025-06-29 | 2025Q12025-03-30 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $567.78M | $570.33M | $548.26M | $568.98M | $566.95M | $442.52M | $414.26M | $442.01M |
| Cost of revenue | $199.00M | $238.62M | $240.84M | -$250.45M | $274.90M | $176.69M | $158.83M | $355.49M |
| Gross profit | $368.79M | $331.71M | $307.43M | $307.45M | $292.05M | $265.83M | $255.43M | $268.79M |
| R&D expense | $42.98M | $45.12M | $44.39M | $12.63M | $44.26M | $26.49M | $25.30M | $44.55M |
| SG&A expense | $220.72M | $213.51M | $226.01M | $614,000 | $207.38M | $137.50M | $152.91M | $254.55M |
| Operating income | $105.43M | $72.82M | $20.18M | $13.87M | -$62.44M | $91.14M | $75.80M | $52.40M |
| Interest expense | $21.21M | $27.95M | $25.72M | $28.13M | $31.83M | $21.70M | $18.54M | $18.64M |
| Pretax income | $83.12M | $45.14M | -$3.83M | -$12.42M | -$92.44M | $70.66M | $58.75M | -$126.76M |
| Income tax | $28.84M | $3.38M | $1.01M | -$30.78M | -$34.01M | $2.49M | $6.42M | $9.90M |
| Net income | $927.43M | $99.69M | -$8.15M | -$714.33M | -$408.89M | $122.58M | $95.00M | -$136.66M |
| EBITDA | $157.01M | $122.64M | $73.93M | $67.45M | -$13.78M | $128.03M | $114.42M | — |
| EPS (basic) | 22.36 | 2.29 | -0.18 | -16.15 | -9.24 | 2.77 | 2.08 | -2.95 |
| EPS (diluted) | 22.28 | 2.28 | -0.18 | -16.15 | -9.24 | 2.77 | 2.07 | -2.93 |
| Dividends declared per share | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
| Weighted avg. shares (diluted) | 41.63M | 43.66M | 44.26M | — | 44.24M | 44.33M | 45.93M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $430.46M | $300.16M | $309.41M | $378.56M | $336.51M | $256.56M | $282.08M | $247.85M |
| Receivables | $379.64M | $364.61M | $365.53M | $345.58M | $592.65M | $513.81M | $464.52M | $226.73M |
| Inventory | $384.42M | $351.91M | $380.86M | $404.39M | $802.47M | $693.69M | $643.97M | $306.77M |
| Current assets | $1.84B | $1.88B | $1.86B | $1.94B | $1.99B | $1.72B | $1.54B | $1.47B |
| PP&E, net | $470.38M | $475.64M | $476.95M | $498.28M | $700.59M | $548.96M | $518.92M | $308.46M |
| Goodwill | $2.29B | $2.29B | $2.30B | $2.31B | $2.54B | $2.69B | $2.65B | $1.99B |
| Intangibles | $1.40B | $1.45B | $1.49B | $1.52B | $2.41B | $2.18B | $2.23B | $1.35B |
| Total assets | $6.35B | $6.79B | $6.78B | $6.95B | $7.87B | $7.38B | $7.16B | $7.10B |
| Current liabilities | $917.10M | $720.38M | $728.05M | $762.03M | $773.03M | $716.15M | $675.91M | $649.36M |
| Short-term debt | $87.50M | $87.50M | $103.12M | $100.00M | $100.00M | $100.00M | $100.00M | $100.00M |
| Long-term debt | $1.53B | $2.72B | $2.51B | $2.54B | $2.57B | $1.80B | $1.81B | $1.56B |
| Total debt | $1.62B | $2.81B | $2.62B | $2.64B | $2.67B | $1.90B | $1.91B | $1.66B |
| Total liabilities | $2.85B | $3.88B | $3.70B | $3.82B | $4.05B | $3.13B | $3.07B | $2.82B |
| Shareholders' equity | $3.49B | $2.90B | $3.08B | $3.12B | $3.82B | $4.24B | $4.10B | $4.28B |
| Net debt | $1.19B | $2.51B | $2.31B | $2.26B | $2.33B | $1.65B | $1.63B | $1.41B |
| Cash flow statement | ||||||||
| Operating cash flow | $96.28M | $91.90M | $46.66M | -$92.29M | $19.57M | -$37.02M | $27.72M | $202.64M |
| Capital expenditure | $21.61M | $14.03M | $18.79M | $651,000 | $19.50M | $27.79M | $24.13M | $32.02M |
| Free cash flow | $74.66M | $77.86M | $27.87M | -$92.94M | $69,000 | -$64.81M | $3.59M | $170.61M |
| Investing cash flow | -$20.36M | -$6.58M | -$74.78M | $14.13M | -$755.74M | -$23.65M | -$22.91M | -$23.09M |
| Financing cash flow | -$1.51B | -$82.00M | -$44.98M | -$61.61M | $756.34M | -$23.67M | -$59.52M | -$119.11M |
| Depreciation & amortization | $51.58M | $49.82M | $53.74M | $53.58M | $48.66M | $36.89M | $38.62M | -$41.27M |
| Stock-based compensation | $6.27M | $5.44M | $6.74M | $2.90M | $6.71M | $5.66M | $6.63M | $7.62M |
| Dividends paid | $13.92M | $14.78M | $15.05M | $15.03M | $15.02M | $15.03M | $15.19M | $15.73M |
| Share buybacks | $304.95M | $250.00M | $0 | $0 | $0 | $0 | $300.00M | $0 |
Free plan shows the latest 8 periods; Pro shows all 73 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.